Correlation Between Medigen Vaccine and GeneReach Biotechnology

Can any of the company-specific risk be diversified away by investing in both Medigen Vaccine and GeneReach Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Medigen Vaccine and GeneReach Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Medigen Vaccine Biologics and GeneReach Biotechnology, you can compare the effects of market volatilities on Medigen Vaccine and GeneReach Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Medigen Vaccine with a short position of GeneReach Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Medigen Vaccine and GeneReach Biotechnology.

Diversification Opportunities for Medigen Vaccine and GeneReach Biotechnology

0.85

Correlation Coefficient

Medigen Vaccine  GeneReach Biotechnology

Very poor diversification

The 3 months correlation between Medigen and GeneReach is 0.85. Overlapping area represents the amount of risk that can be diversified away by holding Medigen Vaccine Biologics and GeneReach Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on GeneReach Biotechnology and Medigen Vaccine is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Medigen Vaccine Biologics are associated (or correlated) with GeneReach Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of GeneReach Biotechnology has no effect on the direction of Medigen Vaccine i.e., Medigen Vaccine and GeneReach Biotechnology go up and down completely randomly.

Pair Corralation between Medigen Vaccine and GeneReach Biotechnology

Assuming the 90 days trading horizon Medigen Vaccine Biologics is expected to under-perform the GeneReach Biotechnology. In addition to that, Medigen Vaccine is 1.37 times more volatile than GeneReach Biotechnology. It trades about -0.26 of its total potential returns per unit of risk. GeneReach Biotechnology is currently generating about -0.21 per unit of volatility. If you would invest  3,175  in GeneReach Biotechnology on September 14, 2024 and sell it today you would lose (450.00) from holding GeneReach Biotechnology or give up 14.17% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Medigen Vaccine Biologics  vs.  GeneReach Biotechnology

Medigen Vaccine Biologics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Medigen Vaccine Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

GeneReach Biotechnology

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days GeneReach Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Pair Trading with Medigen Vaccine and GeneReach Biotechnology

The main advantage of trading using opposite Medigen Vaccine and GeneReach Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Medigen Vaccine position performs unexpectedly, GeneReach Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GeneReach Biotechnology will offset losses from the drop in GeneReach Biotechnology's long position.

The idea behind Medigen Vaccine Biologics and GeneReach Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.